Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Theresa Eifert"'
Autor:
Nuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M. Schnoeder, Theresa Eifert, Chen-Jen Hsu, Florian Perner, Qirui Zhang, Daniela V. Wenge, Fynn M. Hansen, Joanna M. Kirkpatrick, Nidhi Jyotsana, Steven W. Lane, Björn von Eyss, Aniruddha J. Deshpande, Michael W. M. Kühn, Juerg Schwaller, Clemens Cammann, Ulrike Seifert, Frédéric Ebstein, Elke Krüger, Andreas Hochhaus, Michael Heuser, Alessandro Ori, Matthias Mann, Scott A. Armstrong, Florian H. Heidel
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-21 (2023)
Abstract Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents. This points to a need for thera
Externí odkaz:
https://doaj.org/article/32a44bd3490c43d78d23fc64b13aaac5
Autor:
Jasmin Straube, Theresa Eifert, Therese Vu, Yashaswini Janardhanan, Rohit Haldar, Björn von Eyss, Leanne Cooper, Claudia Bruedigam, Victoria Y. Ling, Emily Cooper, Ann-Marie Patch, Lars Bullinger, Tina M. Schnoeder, Megan Bywater, Florian H. Heidel, Steven W. Lane
Publikováno v:
Leukemia. 37:741-750
Murine models offer a valuable tool to recapitulate genetically defined subtypes of AML, and to assess the potential of compound mutations and clonal evolution during disease progression. This is of particular importance for difficult to treat leukem
Autor:
Philipp Ernst, Tina M. Schnöder, Nicolas Huber, Florian Perner, Ashok Kumar Jayavelu, Theresa Eifert, Chen-Jen Hsu, Nuria Tubío-Santamaría, Carl C. Crodel, Martin Ungelenk, Christian A. Hübner, Joachim H. Clement, Andreas Hochhaus, Florian H. Heidel
Publikováno v:
Leukemia. 36:1843-1849
Mutations of the JAK2 gene are frequent aberrations in the aging hematopoietic system and in myeloid neoplasms. While JAK-inhibitors efficiently reduce hyperinflammation induced by the constitutively active mutated JAK2 kinase, the malignant clone an
Autor:
Florian Perner, Peter R. Mertens, Andreas Hochhaus, Scott A. Armstrong, Charlie Hatton, Sabine Brandt, Ciara Murphy, Matthias Mann, Nicolas Schröder, Ashok Kumar Jayavelu, Birgit Perner, Tina M. Schnoeder, Yijun Xiong, Anna Mandinova, Kristina Todorova, Jessica I. Hoell, Theresa Eifert, Nicolas Huber, Nomusa Mashamba, Florian H. Heidel, Nuria Tubio Santamaria, Maximilian Hartmann
Publikováno v:
Leukemia
Persistence of malignant clones is a major determinant of adverse outcome in patients with hematologic malignancies. Despite the fact that the majority of patients with acute myeloid leukemia (AML) achieve complete remission after chemotherapy, a lar
Autor:
Theresa Eifert, Tina M. M Schnoeder, Chen-Jen Hsu, Alicia L Becker, Qirui Zhang, Juliane Mohr, Stephanie Frey, Sebastian Scholl, Lars Bullinger, Steven W Lane, Florian H. Heidel
Publikováno v:
Blood. 140:8680-8681
Autor:
Chen-Jen Hsu, Tina M. M Schnoeder, Theresa Eifert, Qirui Zhang, Oliver Meers, David Corujo, Maximilian Lassi, Raffaele Teperino, Stefan Dimitrov, Holger Bierhoff, Björn von Eyss, Florian Perner, Marcus Buschbeck, Florian H. Heidel
Publikováno v:
Blood. 140:726-727
Autor:
Tina M Schnoeder, Florian Perner, Ashok Kumar Jayavelu, Lianghao Mao, Qirui Zhang, Chen-Jen Hsu, Theresa Eifert, Uwe Grunwald, Peter Mertens, Dhanir Tailor, Akram Taherinasab, Theodore P. Braun, Sanjay Malhotra, Florian H. Heidel
Publikováno v:
Blood. 140:491-492
Autor:
Steven W. Lane, Florian Perner, Nicolas Huber, Florian H. Heidel, Elizabeth Ng, Andreas Hochhaus, Edouard G. Stanley, Zhu Chen, Chen-Jen Hsu, Monica Nafria, Ashok Kumar Jayavelu, Lars Bullinger, Lu Jiang, Klaus-Dieter Fischer, Constanze Bonifer, Matthias Mann, Marcus Buschbeck, Steffen Brodt, Holger Bierhoff, Tina M. Schnoeder, Adrian Schwarzer, Sai-Juan Chen, Joanna Kirkpatrick, Georg Matziolis, Olaf Heidenreich, Patricia Arreba-Tutusaus, Theresa Eifert, Björn von Eyss, Chun-Wei Chen, Konstanze Döhner, Andrew G. Elefanty, Anna Dolnik, Yuting Dai, Sophie G Kellaway, Anetta Ptasinska, Salam A. Assi, Alessandro Ori
Publikováno v:
Blood
In an effort to identify novel drugs targeting fusion-oncogene–induced acute myeloid leukemia (AML), we performed high-resolution proteomic analysis. In AML1-ETO (AE)-driven AML, we uncovered a deregulation of phospholipase C (PLC) signaling. We id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc5d880ca55311258241635b370c0f4
http://edoc.mdc-berlin.de/21022/1/21022oa.pdf
http://edoc.mdc-berlin.de/21022/1/21022oa.pdf
Autor:
Lars Bullinger, Carolin Kathner, Steven W. Lane, Salam A. Assi, Florian Gras, Holger Bierhoff, Marcus Buschbeck, Olaf Heidenreich, Monica Nafria I Fedi, Elizabeth Ng, Florian H. Heidel, Georg Matziolis, Alessandro Ori, Adrian Schwarzer, Konstanze Döhner, Anna Dolnik, Andrew G. Elefanty, Patricia Arreba-Tutusaus, Theresa Eifert, Joanna Kirkpatrick, Anetta Ptasinska, Florian Perner, Klaus-Dieter Fischer, Claudia Bruedigam, Constanze Bonifer, Björn von Eyss, Tina M Schnoeder
Publikováno v:
Blood. 134:531-531
Chromosomal translocations found in acute myeloid leukemia (AML) can generate oncogenic fusions with aberrant epigenetic and transcriptional functions. However, direct therapeutic targeting of leukemia fusion proteins has not been accomplished so far